The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02413762|
Recruitment Status : Unknown
Verified March 2015 by Imperial College London Diabetes Centre.
Recruitment status was: Recruiting
First Posted : April 10, 2015
Last Update Posted : April 10, 2015
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus, Type 2||Other: No intervention|
Iron overload and mechanisms inducing insulin resistance are reciprocally linked. Dietary iron absorption, and iron uptake in liver and adipose tissue, are regulated through the hormone hepcidin. Iron is implicated in microvascular and macrovascular disease pathways and therefore hepcidin may represent a biomarker for progression to complications in type 2 diabetes mellitus.
Serum pancreatic polypeptide levels correlate with visceral adiposity and may therefore contribute to the diagnosis of, and risk stratification in, the metabolic syndrome.
Measuring iron status, incretin hormones and serum pancreatic polypeptide will facilitate discrimination of patients at risk of vascular complications of T2DM and clinically significant non-alcoholic fatty liver disease.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus|
|Study Start Date :||March 2015|
|Estimated Primary Completion Date :||August 2017|
|Estimated Study Completion Date :||August 2017|
NGT, no insulin resistance
Individuals with normal glucose tolerance without a diagnosis of IGF, IGT or Diabetes Mellitus. No intervention.
Individuals with a diagnosis of impaired glucose tolerance, impaired fasting glucose or type 2 diabetes mellitus. No intervention.
Insulin resistance without IGT
e.g. polycystic ovarian syndrome. No intervention.
IGT, no insulin resistance
e.g. T1DM. No intervention.
Previous metabolic surgery
Previous metabolic surgery for weight loss or treatment of T2DM. No intervention.
Other: No intervention
- Vascular complications of diabetes mellitus [ Time Frame: 2 years ]
- Progression to NAFLD or NASH [ Time Frame: 2 years ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02413762
|Contact: Nader Lessan, MBBS FRCP MD||+971 2 404 firstname.lastname@example.org|
|Contact: Adam J Buckley, MRCP MRes||+971 2 404 0800 ext email@example.com|
|United Arab Emirates|
|Imperial College London Diabetes Centre||Recruiting|
|Abu Dhabi, United Arab Emirates, 48338|
|Contact: Nader Lessan, MBBS MD FRCP +971 2 404 0800 firstname.lastname@example.org|
|Contact: Adam J Buckley, MRCP MRes +971 2 404 0800 ext 504 email@example.com|
|Principal Investigator: Nader Lessan, MBBS MD FRCP|
|Sub-Investigator: Adam J Buckley, MRCP MRes|
|Principal Investigator:||Nader Lessan, MBBS FRCP MD||Imperial College London Diabetes Centre|